Key Takeaways
- Three senior Oklo executives completed stock transactions totaling over $21M on April 1, including CEO Jacob DeWitte and COO Caroline Cochran who each sold approximately $10M.
- DeWitte’s selling pattern extends back to January, with transactions executed at various price points from approximately $100 down to $50.
- CNBC’s Jim Cramer expressed skepticism about Oklo’s near-term profitability prospects, describing the company as lacking commercial viability.
- The company’s recent quarterly results showed a loss of $0.27 per share, falling short of the anticipated -$0.17 estimate.
- Wall Street maintains a “Moderate Buy” stance with an $84.30 average price target, though multiple firms have reduced their projections recently.
On April 1, 2026, Oklo’s executive leadership executed significant stock transactions worth more than $21 million collectively, with all sales occurring through previously established Rule 10b5-1 trading arrangements.
CEO Jacob DeWitte’s transactions involved shares sold at weighted average prices spanning $48.41 to $51.20, generating proceeds of $10,069,852. Following these sales, DeWitte maintains direct ownership of 691,533 Class A shares, with indirect holdings exceeding 20 million additional shares.
Co-founder and COO Caroline Cochran executed sales generating identical proceeds of $10,069,852, with transaction prices ranging from approximately $47.99 to $51.79 per share. Her direct shareholding stands at 658,039 shares after the transactions.
CFO Richard Bealmear’s transaction involved 16,342 shares at $51.08, yielding $834,749. His remaining position includes 386,008 Class A shares.
Each transaction followed Rule 10b5-1 trading protocols, which executives establish beforehand to demonstrate trades occur independently of material nonpublic information.
DeWitte’s April 1 activity represents a continuation of an established selling pattern beginning in January. Previous transactions occurred at higher valuations, including shares sold near $112, $75, and $63. Combined, these transactions have generated proceeds in the tens of millions throughout recent months.
The April 1 transaction volume of 200,000 shares across two separate sales represented a 17.58% decrease in his directly held position.
Cramer’s Perspective
These executive transactions occurred while CNBC’s Jim Cramer voiced reservations about the company’s financial outlook. During a recent broadcast, Cramer stated: “Oklo, while not a science project, has very little prospects for making any money any time in the future that we think is important for a stock.”
Cramer had previously articulated similar views in January, characterizing Oklo as lacking commercial operations and suggesting that established players like GE Vernova hold superior positioning within the nuclear power sector due to their operational infrastructure.
Financial Results and Wall Street Views
Regarding fundamental performance, Oklo disclosed a quarterly loss of $0.27 per share, representing a shortfall of $0.10 compared to the consensus forecast of -$0.17.
Despite this underperformance, analyst sentiment remains predominantly positive, though with tempered price expectations. UBS revised its target downward from $95 to $60 while assigning a neutral rating. Needham adjusted its projection from $135 to $73, and Canaccord reduced its target from $175 to $125. Cantor Fitzgerald maintained an overweight rating with a $122 price objective.
Wall Street’s consensus target currently stands at $84.30, accompanied by a “Moderate Buy” rating. The analyst community’s breakdown includes two Strong Buy ratings, nine Buy recommendations, six Hold positions, and two Sell ratings.
The stock’s 12-month trading range extends from $17.42 to $193.84. Current technical indicators show the 50-day moving average positioned at $64.62, while the 200-day moving average sits at $93.16.
